Akzo shares slide on mixed trial results

Shares of Akzo Nobel slid after the drug developer announced mixed results in a Phase III trial of asenapine for schizophrenia. The drug's performance in another half of the study devoted to acute mania associated with bipolar disorder was positive. But analysts quickly seized on the uncertain results for the drug in schizophrenia, noting that Akzo needs to clearly distinguish the drug from others in the field.

- read the report on Akzo from MarketWatch

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.